Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Corporate Update (Dec 20, 2024)

Reports
Other Events
Filing Date
Filed December 20, 2024
Period End
December 20, 2024
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed December 20, 2024. Cited figures are marked; the original filing is the authoritative source.

On December 20, 2024, Neurocrine Biosciences, Inc. filed a Form 8-K under Item 8.01 (Other Events) announcing that CRENESSITY (crinecerfont) capsules and oral solution are now available in the United States.

The drug was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). The filing attaches a press release (Exhibit 99.1) describing CRENESSITY as a first-in-class oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist. The Company has set a wholesale acquisition cost of approximately $38,333a for a 30-day supply in the United States, and approximately $19,167 for a 30-day supply for pediatric patients weighing less than 20 kilograms.

The Company expects 90% of patients will have a monthly copay of $12b or less. Access is centralized through PANTHERx Rare, a specialty pharmacy, and the Company offers a free patient assistance program, Neurocrine Access Support.

The filing's forward-looking statements flag risks including adequate third-party reimbursement, the Company's dependence on third parties for development and manufacturing, and the commercialization of CRENESSITY. The press release states that the approval was supported by the CAHtalyst Pediatric study (103 patients aged four to 17) and the CAHtalyst Adult study (182 patients aged 18 to 58), and that the open-label extension portions of both studies are ongoing.

Key Highlights

  1. CRENESSITY (crinecerfont) is now commercially available in the U.S. following FDA approval as an adjunctive treatment to glucocorticoid replacement for classic congenital adrenal hyperplasia in patients four years and older.
  2. Wholesale acquisition cost is approximately $38,333 for a 30-day supply; approximately $19,167 for a 30-day supply for pediatric patients weighing less than 20 kilograms.
  3. The Company expects 90% of patients will have a monthly copay of $12 or less.
  4. Prescriptions are exclusively routed through PANTHERx Rare, a specialty pharmacy with CAH-trained pharmacists available 24/7.
  5. Neurocrine Access Support, a free assistance program with a dedicated Care Coordinator, is available to patients, caregivers and healthcare providers.
  6. Approval was supported by the CAHtalyst Pediatric study (103 patients aged four to 17) and CAHtalyst Adult study (182 patients aged 18 to 58), described as the largest-ever clinical trial program in classic CAH.
  7. Key risks cited include adequate third-party reimbursement, dependence on third parties for development and manufacturing, and the pace of commercialization.

Frequently Asked Questions

  1. What is CRENESSITY and what is it approved to treat?

    CRENESSITY (crinecerfont) is an oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist. It is approved by the FDA as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia. It is available as capsules in 50 mg and 100 mg doses and as a 50 mg/mL oral solution.

  2. What will CRENESSITY cost patients and payors?

    The Company has established a wholesale acquisition cost of approximately $38,333 for a 30-day supply in the United States, or approximately $19,167 for a 30-day supply for pediatric patients weighing less than 20 kilograms. The Company expects 90% of patients will have a monthly copay of $12 or less.

  3. How will patients get access to CRENESSITY?

    CRENESSITY is available exclusively through PANTHERx Rare, a specialty pharmacy, to centralize prescriptions. The Company also offers Neurocrine Access Support, a free program with a dedicated Care Coordinator to help patients navigate insurance and identify financial assistance options.

  4. What clinical data supported the approval?

    The approval was supported by the CAHtalyst Pediatric study, which included 103 patients aged four to 17, and the CAHtalyst Adult study, which included 182 patients aged 18 to 58. The press release describes these as the largest-ever clinical trial program in classic CAH. The open-label extension portions of both studies are ongoing.

  5. What are the main risks identified in the filing?

    The filing cites risks including whether CRENESSITY receives adequate reimbursement from third-party payors, the Company's dependence on third parties for development and manufacturing, and the commercialization of CRENESSITY. The press release also lists market uptake, competitive products, and regulatory and post-approval commitments as risk factors.